PT Bundamedik Tbk

Jakarta Stock Exchange BMHS.JK

PT Bundamedik Tbk EBITDA Margin for the year ending December 31, 2023: 13.67%

PT Bundamedik Tbk EBITDA Margin is 13.67% for the year ending December 31, 2023, a -34.11% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

PT Bundamedik Tbk EBITDA Margin for the year ending December 31, 2022 was 20.75%, a -37.76% change year over year.
PT Bundamedik Tbk EBITDA Margin for the year ending December 31, 2021 was 33.33%, a 43.96% change year over year.
PT Bundamedik Tbk EBITDA Margin for the year ending December 31, 2020 was 23.15%, a 43.39% change year over year.
PT Bundamedik Tbk EBITDA Margin for the year ending December 31, 2019 was 16.15%, a 12.31% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Jakarta Stock Exchange: BMHS.JK

PT Bundamedik Tbk

CEO	Mr. Agus Heru Darjono
IPO Date	July 6, 2021
Location	Indonesia
Headquarters	Jl. Teuku Cik Ditiro No.28
Employees	1,434
Sector	Health Care
Industries Hospitals & Clinics

Description

PT Bundamedik Tbk provides health care services in Indonesia. As of December 31, 2021, the company operated 2 maternal and child hospitals, 3 general hospitals, 2 clinics, 10 IVF clinics, and 14 diagnostic laboratories. It also engages in the distribution of drugs, pharmaceuticals, and medical devices; and hotel, medical tourism, and management consulting businesses. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Bunda Medik is a subsidiary of PT Bunda Investama Indonesia.

Key trends

Past 5 years